TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8949825
Drug: Exogenous PCHE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exogenous PCHE equivalent to activity present in 25 ml kg‐1 of human plasma (group PCHE)
Study: 8949825
Drug: Edrophonium 1
Normalized name: edrophonium 10 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edrophonium 1 mg kg‐1 and exogenous PCHE (combination group)
Study: 7014073
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg doxpicomine
Study: 31833868
Drug: Heparin prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin prophylaxis during the third trimester
Study: 31833868
Drug: No antepartum
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antepartum heparin prophylaxis
Study: 31301146
Drug: Adjunctive PAD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive PAD (red LED, 635 nm, photosensitive dye, 0.01% tolonium chloride)
Study: 31301146
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no adjunctive PAD)
Study: 31301146
Drug: Adjunctive PAD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive PAD
Study: 28160084
Drug: N‐3 PUFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: N‐3 PUFA (2330 mg day‐1)
Study: 27969041
Drug: Daily journal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily journal writing as reinforcement for resourcefulness training (RT) over a four-week period.
Study: 22406990
Drug: BMS +
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BMS + high-dose oral sirolimus (initial dose of 15 mg, followed by 6 mg/day for four weeks)
Study: 22406990
Drug: BMS +
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BMS + low-dose sirolimus (6 mg followed by 2 mg daily for four weeks)
Study: 22406990
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (BMS + high-dose sirolimus, BMS + low-dose sirolimus, BMS without sirolimus)
Study: 19054608
Drug: Botulinum neurotoxin
Normalized name: Botulinum neurotoxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum neurotoxin type A (BoNTA) treatment
Study: 9829604
Drug: Continuous nasogastric
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous nasogastric infusion of liquid feeding (4.2 kJ/mL, energy provision 1 x the initial predicted basal metabolic rate; 3 days)
Study: 9829604
Drug: Continuous nasogastric
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous nasogastric infusion of colored water (2 days)
Study: 9829604
Drug: Continuous nasogastric
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous nasogastric infusion of liquid feeding (4.2 kJ/mL)
Study: 2780070
Drug: Ketanserin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (10 mg for upper limb pain, 20 mg for lower limb pain)
Study: 25732032
Drug: Palliative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palliative treatment (use of aspirin and analgesics only, no reperfusion)
Study: 25732032
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (any treatment including antithrombotics or anticoagulants, but no reperfusion)
Study: 25732032
Drug: Reperfusion treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reperfusion treatment (thrombolysis and/or percutaneous coronary intervention)
Study: 23788306
Drug: Intracoronary (IC)
Normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary (IC) bolus of GP IIb/IIIa inhibitor
Study: 23788306
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) bolus of GP IIb/IIIa inhibitor
Study: 19187417
Drug: Occupational and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational and physical therapy sessions to instruct participants in compensatory strategies, home modifications, home safety, fall recovery techniques, and balance and muscle strength exercises.
Study: 15885050
Drug: Tolperisone (300-900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolperisone (300-900 mg daily)
Study: 11408847
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (6-g load then 2 g/hr)
Study: 9312708
Drug: Metal implants
Normalized name: menthone 1,2-glycerol ketal, (-)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metal implants
Study: 9312708
Drug: Polyactide implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyactide implants
Study: 8358527
Drug: Intramuscular interferon‐alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular interferon‐alpha
Study: 8358527
Drug: CO2 laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: CO2 laser ablation plus intramuscular interferon‐alpha
Study: 3117084
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate (SCG) administered to the nasal mucosa 30 min before provocation with histamine
Study: 3117084
Drug: Clemastine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clemastine administered to the nasal mucosa 30 min before provocation with histamine
Study: 3117084
Drug: Ketotifen administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen administered to the nasal mucosa 30 min before provocation with histamine
Study: 3117084
Drug: Placebo (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline control solution) administered prior to provocation
Study: 3117084
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate (SCG), clemastine, and ketotifen administered to the nasal mucosa 30 min before provocation with allergen
Study: 17925050
Drug: Slow-release vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release vitamin C tablets (500 mg/d) and vitamin E (182 mg/d) for 4 weeks
Study: 17925050
Drug: Well-nourished subjects
Normalized name: Lantiseptic Nourishing Skin
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Well-nourished subjects consuming 600 g fruits and vegetables or equivalent vitamins and minerals for 24 days
Study: 16194620
Drug: Supervised aerobic
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Supervised aerobic and resistance training program twice a week for five months
Study: 10786405
Drug: Sertaconazole monodose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertaconazole monodose vaginal suppository only (group O)
Study: 10786405
Drug: Sertaconazole monodose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertaconazole monodose vaginal suppository combined with sertaconazole cream applied to the vulvar area for 7 days (group OC)
Study: 8267679
Drug: Bromfenac 75
Normalized name: bromfenac 0.75 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromfenac 75 mg
Study: 3009726
Drug: Postoperative CAP
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative CAP chemotherapy (Cytoxan, Adriamycin, and cisplatin)
Study: 7988247
Drug: Bacillus Calmette‐Guerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacillus Calmette‐Guerin (BCG) and levamisole immunotherapy
Study: 24604243
Drug: Ketoconazole 400
Normalized name: ketoconazole 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole 400 mg once daily for 14 days
Study: 24604243
Drug: Diltiazem 300
Normalized name: diltiazem 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 300 mg once daily for 11 days
Study: 22313564
Drug: Oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo solution
Study: 15635348
Drug: 1,000 mg
Normalized name: bran 1,000 mg ORAL WAFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg of S oblonga extract
Study: 15635348
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg of S oblonga extract (control)
Study: 12131561
Drug: Lacidipine 4
Normalized name: lacidipine 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacidipine 4 mg o.i.d.
Study: 10958373
Drug: 6.9% carbohydrate-electrolyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.9% carbohydrate-electrolyte solution (CES)
Study: 1748537
Drug: Film-coated tablet
Normalized name: ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Film-coated tablet
Study: 1610425
Drug: New enteric-coated
Normalized name: EC-0652
DrugBank: EC-0652 (DB15340)
Approvals — FDA: no, EMA: no, PMDA: no
Description: New enteric-coated pellet preparation
Study: 23505172
Drug: Metformin (2,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (2,000 mg/d)
Study: 30497904
Drug: SB spray
Normalized name: SB 224289
DrugBank: SB 224289 (DB17052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB spray
Study: 30107350
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg intravenous (IV) ketamine
Study: 23082557
Drug: Nevirapine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nevirapine (400 mg/day)
Study: 23082557
Drug: Efavirenz (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efavirenz (600 mg/day)
Study: 18626267
Drug: Citalopram (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (10 mg/d)
Study: 18626267
Drug: Clomipramine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine (25 mg/d)
Study: 18626267
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment groups (Citalopram and Clomipramine)
Study: 10331828
Drug: Ceftazidime treatment
Normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftazidime treatment (postintervention)
Study: 10331828
Drug: Ceftazidime treatment
Normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftazidime treatment (preintervention)
Study: 7490172
Drug: Intra-articular injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injections of 750 mcg of somatostatin 14 (SST14) at 15-day intervals
Study: 7490172
Drug: Intra-articular injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injections of 750 mcg of somatostatin 14 (SST14)
Study: 25455003
Drug: Fostamatinib 100
Normalized name: fostamatinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fostamatinib 100 mg bid
Study: 23378467
Drug: Fostamatinib 100
Normalized name: fostamatinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fostamatinib 100 mg qd
Study: 15943851
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of famotidine (40 mg/day)
Study: 15943851
Drug: Drip infusion
Normalized name: DRIP COLLECTOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drip infusion of omeprazole (40 mg/day)
Study: 12600912
Drug: Acetylcysteine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetylcysteine (600 mg BID)
Study: 10846331
Drug: 800 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 micrograms misoprostol vaginally at home (self-administered)
Study: 9387637
Drug: Placebo medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo medicine (Control)
Study: 6481116
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of prednisone (oral dose)
Study: 24367796
Drug: Biological male
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological male personnel
Study: 23117776
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg dexamethasone
Study: 20227579
Drug: Long-pulsed neodymium:yttrium-aluminium-garnet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-pulsed neodymium:yttrium-aluminium-garnet laser treatment
Study: 20227579
Drug: Topical benzoyl
Normalized name: benzoyl peroxide Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical benzoyl peroxide and clindamycin (Control)
Study: 12181386
Drug: Prednisolone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (30 mg daily for 1 week)
Study: 1951997
Drug: 1.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg/kg suxamethonium
Study: 1951997
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg suxamethonium
Study: 7019782
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release indomethacin capsules
Study: 7019782
Drug: Oral route
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral route of medication (sustained release indomethacin)
Study: 31451704
Drug: Rice bran
Normalized name: Rice bran
DrugBank: Rice bran (DB14361)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rice bran extract supplement (RBS) 1,000 mg/day
Study: 27523583
Drug: DASH diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: DASH diet among participants with baseline serum UA ≥7 mg/dl (n=8)
Study: 24366395
Drug: Heart failure
Normalized name: INVESTIGATIONAL CONGESTIVE HEART FAILURE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heart failure drugs (β-blockers, diuretics, ACEIs/ARBs)
Study: 22484777
Drug: Beta-blockade (BB)
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockade (BB) therapy
Study: 8913402
Drug: Emla cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Emla cream (5%)
Study: 6341350
Drug: Cefotetan (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotetan (1 or 2 g every 12 h)
Study: 6341350
Drug: Cefoxitin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin (1 or 2 g every 8 h)
Study: 28722480
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro (Ly-Lis)
Study: 24957256
Drug: Regorafenib 160
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib 160 mg daily plus best supportive care (BSC)
Study: 14658584
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with platinum analogues
Study: 14658584
Drug: Various combinations
Normalized name: various combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various combinations of cytostatic drugs
Study: 9061681
Drug: Treated bednets
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treated bednets (lambdacyhalothrin 10 mg/m2)
Study: 8117508
Drug: Follow-up scintimetry
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Follow-up scintimetry after conservative treatment and osteosynthesis
Study: 4027120
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal 50 g in 300 ml of water
Study: 4027120
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal 50 g administered immediately after PAS 10 g or 20 g
Study: 29917069
Drug: 0 µg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 µg/d vitamin D3
Study: 29917069
Drug: 10 µg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 µg/d vitamin D3
Study: 29917069
Drug: 20 µg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 µg/d vitamin D3
Study: 27089843
Drug: Parenteral nutritional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutritional support for 5 days (n=1200)
Study: 7475658
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg primaquine base daily (double‐blinded)
Study: 7475658
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg chloroquine base weekly (open)
Study: 1942917
Drug: Solcoseryl ophthalmic
Normalized name: Solcoseryl
DrugBank: Solcoseryl (DB15794)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solcoseryl ophthalmic gel
Study: 1942917
Drug: 2.4% cysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.4% cysteine in ophthalmic gel
Study: 31180833
Drug: Hybrid robotic
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid robotic system combining EMG-Triggered FES with a passive exoskeleton for upper limb suspension during a structured exercise program of 27 sessions lasting 30 min each.
Study: 28326680
Drug: Desmopressin 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin 0.3 μg/kg administered 30 min before surgery
Study: 28326680
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline administered 30 min before surgery
Study: 25007542
Drug: Active light
Normalized name: Ensure Active Light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active light treatment (ALT)
Study: 25007542
Drug: Placebo light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo light treatment (L-PBO)
Study: 15023808
Drug: Simvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 40 mg/d for 6 weeks, then 80 mg/d for 6 weeks, then 80 mg/d for 24 weeks
Study: 15023808
Drug: Atorvastatin 20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20 mg/d for 6 weeks, then 40 mg/d for 6 weeks, then 80 mg/d for 24 weeks
Study: 9280743
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 (prepidil gel) plus oxitocin
Study: 9280743
Drug: Intravenous oxitocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous oxitocin
Study: 8397562
Drug: Nifedipine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (30 mg oral dose)
Study: 8397562
Drug: Terbutaline (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline (subcutaneous injection)
Study: 31094286
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of UCVA and NCAR
Study: 27452202
Drug: Alirocumab (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab (75 mg every 2 weeks, increased to 150 mg if week 8 LDL-C ≥2.6/3.1 mmol/L)
Study: 22082200
Drug: Sustained-release oxycodone
Normalized name: oxycodone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release oxycodone tablets (initial dose of 10mg orally every 12 hours, titrated according to pain intensity)
Study: 22082200
Drug: Sustained-release oxycodone
Normalized name: oxycodone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release oxycodone tablets
Study: 19329063
Drug: Boston Simplus
Normalized name: CONTACT LENS SOLN (BOSTON SIMPLUS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boston Simplus (Bausch & Lomb) multipurpose solution
Study: 17454160
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol (E2)/norethisterone acetate (NETA) (50 microg E2 daily for 14 days followed by 50 microg E2/0.25 microg NETA daily for 14 days; transdermal group, n = 19)
Study: 17454160
Drug: Transdermal continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal continuous E2/oral medroxyprogesterone acetate (MPA) (50 microg E2/5 mg MPA daily; transdermal/oral group, n = 19)
Study: 17454160
Drug: Oral continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral continuous E2/NETA (1 mg E2/0.5 mg NETA daily; oral group, n = 21)
Study: 17454160
Drug: Subcutaneous fat
Normalized name: Sus scrofa subcutaneous fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous fat <33 mm (n = 29)
Study: 17454160
Drug: Subcutaneous fat
Normalized name: Sus scrofa subcutaneous fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous fat >=33 mm (n = 30)
Study: 14962821
Drug: Rifapentine 600
Normalized name: Rifapentine
DrugBank: Rifapentine (DB01201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifapentine 600 mg
Study: 14962821
Drug: Rifapentine 900
Normalized name: Rifapentine
DrugBank: Rifapentine (DB01201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifapentine 900 mg
Study: 14962821
Drug: Rifapentine 1200
Normalized name: Rifapentine
DrugBank: Rifapentine (DB01201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifapentine 1200 mg
Study: 14962821
Drug: Rifapentine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifapentine (all doses)
Study: 11856080
Drug: Balsalazide, 6.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balsalazide, 6.75 g
Study: 11856080
Drug: Sulfasalazine, 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfasalazine, 3 g
Study: 8711365
Drug: Polyene phosphatidylcholine
Normalized name: phosphatidylcholine, soybean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyene phosphatidylcholine (PPC) 2.7 g daily for three months
Study: 335247
Drug: Aspirin 600
Normalized name: aspirin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 600 mg given twice daily
Study: 24325795
Drug: High intensity,
Approvals — FDA: no, EMA: no, PMDA: no
Description: High intensity, 40 s, buccal
Study: 22336009
Drug: Subcutaneous immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous immunotherapy (SCIT) with Alutard SQ, ALK-Abell¨®
Study: 22336009
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) with Chanllergen-Df drops, Wolwo Pharma
Study: 17999779
Drug: N-acetylcysteine (NAC
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC 1.8 g.day(‐1), 3 days)
Study: 17999779
Drug: alpha-lipoic acid
Normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha-lipoic acid (LIP 1.2 g.day(‐1), 3 days)
Study: 17999779
Drug: taurine (TAU
Approvals — FDA: no, EMA: no, PMDA: no
Description: taurine (TAU 3 g.day(‐1), 3 days)
Study: 15697072
Drug: Metformin 850
Normalized name: metFORMIN 850 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 850 mg three times daily